Transaction DateRecipientSharesTypePriceValue
19th November 2020Kathryn E Falberg795Open or private sale$807.84$642,232.80
19th November 2020Kathryn E Falberg20,000Conversion of derivative$0.00
19th November 2020Kathryn E Falberg891Open or private sale$813.04$724,418.64
19th November 2020Kathryn E Falberg232Open or private sale$806.63$187,138.16
19th November 2020Kathryn E Falberg1,853Open or private sale$809.03$1,499,132.59
19th November 2020Kathryn E Falberg5,670Open or private sale$811.00$4,598,370.00
19th November 2020Kathryn E Falberg1,891Open or private sale$815.00$1,541,165.00
19th November 2020Kathryn E Falberg10Open or private sale$814.00$8,140.00
19th November 2020Kathryn E Falberg200Open or private sale$811.68$162,336.00
19th November 2020Kathryn E Falberg2,852Open or private sale$810.19$2,310,661.88
Arcus Biosciences
Arcus Biosciences logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.


Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.


Ticker: RCUS
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1724521
Employees: 139
Exchange: New York Stock Exchange
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $285 M (0%)
Assets, Current: $472 M (144%)
Property, Plant and Equipment, Net: $8 M (-11%)
Other Assets, Noncurrent: $1 M (51%)
Assets: $481 M (137%)
Accounts Payable, Current: $12 M (156%)
Accrued Liabilities, Current: $6 M (0%)
Liabilities, Current: $40 M (76%)
Other Liabilities, Noncurrent: $693 Th (-14%)
Liabilities: $53 M (34%)
Common Stock, Value, Issued: $6 Th (50%)
Common Stock, Shares, Issued: $59 M (28%)
Retained Earnings (Accumulated Deficit): $278 M (35%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $144 Th (125%)
Stockholders' Equity (Parent): $429 M (0%)
Liabilities and Equity: $481 M (137%)
Revenue: $2 M (-50%)
Research and Development: $36 M (-39%)
General and Administrative Expenses: $11 M (-38%)
Operating Income/Loss: $45 M (-38%)
Other Income, net: $301 Th (-68%)